The world is "on the cusp of a first generation of treatments for Alzheimer's disease", after a new drug was found to slow cognitive and functional decline. Results of a study, released in a preliminary form by drug maker Eli Lilly, show their drug donanemab reduced the rate of cognitive decline of Alzheimer's patients in a trial by between 27 and 35%. Those on the drug were also better able to maintain normal daily activities than patients not receiving it. "This result confirms that we are now entering the treatment era of Alzheimer's disease," said Dr Cath Mummery, clinical lead for the Cognitive Disorders Clinic, at the National Hospital for Neurology and Neurosurgery in London.
Back to top